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Over the past several years, we have been analyzing the reactivity of human sera 
for cell surface antigens of malignant  melanoma and  other  human  tumors  (1-10). 
The  major  focus  of  this  work  has  been  to  determine  whether  patients  develop 
antibodies  that  have specificity for autologous  tumor cells.  The  approach  that  we 
developed  to  answer  this  question  has  been  referred  to  as  autologous  typing  and 
depends  on  (a)  cultured  lines  of tumor  cells  as  target  cells,  (b)  the  use  of several 
serological techniques to identify different classes of immunoglobulin, and (c) absorp- 
tion tests to determine the specificity of the reactions observed. In this way, autologous 
antibodies  have defined  three classes of tumor antigens.  Class  1 antigens are of the 
greatest interest,  as they show an absolute restriction  to autologous tumors and are 
found on no other normal or malignant cell type. Class 2 antigens are shared tumor 
antigens and are found on autologous as well as certain allogeneic tumor cells; recent 
work indicates that some class 2 antigens may also be found on a  restricted range of 
normal cells and therefore should be classified as autoantigenic  differentiation anti- 
gens. 1 By far, the greatest number of reactions found in autologous typing are due to 
antibodies to class 3 antigens. These antigens are found on a  wide variety of normal 
and  malignant  cells  of human  and  animal  origin.  Some class  3  reactivity  can  be 
traced to heterologous serum components used in the culturing of cells, the antigens 
disappearing when the cells are grown in human serum. Other class 3 antigens appear 
to be autoantigenic components that are widely distributed on adult  and fetal cells. 
Absorption  tests  have been  critical  as  a  means  to  distinguish  the  class  of antigens 
detected by autologous typing. 
To date, three class  1 antigens have been defined on human melanoma cells, the 
tumor type that has been most extensively investigated: AU antigen (1, 7), BD antigen 
(2), and BI antigen (3,  11). In this report, we describe a new class 1 melanoma antigen, 
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DX.  This analysis  has  been  particularly  instructive  with  regard  to the  detection  of 
class 1 antigens and may explain why class 1 reactivity is apparently so uncommon in 
melanoma patients. Several melanoma cell lines were derived from separate metastatic 
foci of the same patient  (DX)  and each could be distinguished  from one another on 
the basis of stable phenotypic difference in growth, morphology, and in the expression 
of cell surface antigens and  glycoproteins. Only one of the  lines expressed  sufficient 
levels of DX antigen to allow detection of autologous DX antibody. 
Materials  and Methods 
Tissue Culture.  Melanoma and other cell lines were derived as described previously (1, 5, 6). 
Two human fetal cell lines (Flow 4000 and Flow 5000) were purchased from Flow Laboratories 
(Roekville, Md.). B cell lines from patients with melanoma were derived from peripheral blood 
lymphocytes transformed by Epstein-Barr virus released from the B-95-8 marmoset lymphoid 
line. 
Cultures were maintained in Eagle's minimum essential medium supplemented with 2 mM 
glutamine,  1% nonessential  amino acids,  100 U/ml  penicillin,  100 #g/ml streptomycin, and 
10% fetal bovine serum (FBS).2 To remove heterologous FBS components, melanoma cells were 
cultured in prescreened 10% human sera from AB blood type donors for at least 6 wk (generally 
three subcultures).  Cuhures  were regularly tested  for mycoplasma, fungi, and  bacteria, and 
contaminated cultures were discarded. 
Serological Procedures.  The protein A hemadsorption (PA) and immune adherence assays (IA) 
were performed as described previously (2, 5). For anti-human y-heavy chain assays (anti-'t'G) 
indicator cells were prepared by conjugating the immunoglobulin fraction of  rabbit anti-human 
y-heavy chain (DAKO, Copenhagen) to human O ÷ erythrocytes with 0.01% chromium chloride 
(8). Assays were performed in Falcon 3040 microtest II plates (Falcon Labware, Oxnard, Calif.) 
Target cells (plated  1-2 d previously) and human sera were incubated for 1 h at 37°C (pA and 
anti-TG  ) or 4°C (IA). After washing the target cells, indicator cells were added and incubated 
with target cells for 1 h  (PA and anti-yG assay)  or 30 rain (IA). The plates were then washed 
gently and reactions evaluated under light microscopy. When testing cells grown in medium 
containing human serum,  2%  (wt/vol)  gamma globulin~free  human serum albumin  (Sigma 
Chemical Co., St. Louis, Mo.) in phosphate-buffered saline solution was substituted for the 5% 
gamma globulin-free bovine serum regularly used in the serological assays. Qualitative absorp- 
tion tests were performed by absorbing 30-50/zl of serum (diluted according to the end point) 
with  an equal  volume of washed  packed cells  for  1 h  at  room temperature  and  testing  for 
residual antibody on target cells grown in Falcon 3034 plates (Falcon Labware) (6). 
,Specific Labeling and Analysis of Cell Surface Glycoproteins.  Cells we~ labeled by three procedures, 
as described previously (12): (a) neuraminidase-galactose oxidase-[ H]borohydride, (b) galactose 
oxidase-[ZH]borohydride, and (c) dilute periodate-[3H]borohydride. Labeled glyeoproteins were 
analyzed  by  sodium  dodecyl  sulfate-polyacrylamide  gel  electrophoresis  (SDS-PAGE)  and 
fluorography (13). 
Results 
Clinical History of Patient  DX.  DX is a  70-yr-old white female who presented with 
an enlarging pigmented nevus on the distal third of the left leg in June  1975. She was 
treated surgically by wide excision and prophylactic inguinal lymph node dissection. 
Pathology showed a  Clark's level III malignant  melanoma with  four satellite  lesions 
and  no  evidence  of disease  in  regional  lymph  nodes.  A  metastatic  lesion  in  the 
subcutaneous tissue of the left thigh was excised in September  1978 and a melanoma 
cell  line  (designated  DX-1)  was established  from the surgical specimen.  1 mo later, 
2 Abbreviations used in this paper: anti-'l,G  , anti-human T-heavy chain assay; FBS, fetal bovine serum; tA, 
immune  adherence  assay; PA,  protein  A  hemadsorption  assay; SDS-PAGE, sodium  dodecyl sulfate 
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four additional subcutaneous metastases appeared on the thigh. The patient received 
triweekly subcutaneous vaccinations with irradiated  allogeneic melanoma cells,  SK- 
MEL-13, continuing from November 1978 to July 1979 with no change in the size of 
metastases.  All  visible melanoma lesions were excised in August  1979 and  two new 
melanoma cell lines  from two discrete metastatic deposits were established  in tissue 
culture  (DX-2 and  DX-3).  Vaccination with  irradiated  DX-1  melanoma cells  was 
carried out from November to December 1979. She remained in good health, free of 
evident tumor, until August 1980 when she developed new lesions in the left inguinal 
area. At present, she has multiple soft tissue metastases. 
Morphology  and  Growth Characteristics of Melanoma Cell Lines Derived from Patient 
DX.  Fig.  1 illustrates the characteristic morphology of the three melanoma cell lines 
(DX-1, DX-2, DX-3) established  from three distinct subcutaneous metastases.  DX-1 
and  DX-2 cells  accumulate visible pigmentation;  DX-3 cells  appear unpigmented. 
The DX-2 and DX-3 cell  lines grow as attached monolayers, whereas the DX-1 line 
has a marked tendency to grow in suspension as microcolonies of rounded cells after 
initial attachment. This growth trait of the DX-1 line has been stable over 25 passage 
generations, and both suspension cells and monolayer DX-1 cells can initiate cultures 
in which the cells  first  attach to the substrate and then progressively detach over the 
next  7-14  d.  DX-2 cells  assume  a  characteristic  spindle  shape  during growth and 
Fro.  1 A.  Photomicrograph  of cell line DX-1 (×220), See text for description. ALBINO ET AL.  1767 
FIa.  1 B.  Photomicrograph  of cell line DX-2 (X220). See text for description. 
form multiple layers of cells. DX-3 cells show an epithelial type of morphology and 
tend to be more sensitive to contact inhibition than DX-2 cells. The doubling time 
and  saturation  density of DX-I,  DX-2,  and  DX-3  cell lines were 70 h  and  35,000 
eells/cm  2 (monolayer plus suspension cells), 50 h  and 44,000 cells/cm  2, and 61 h  and 
40,000 cells/era  z, respectively. 
The HLA haplotype of DX-1, DX-2, and DX-3 was identical and corresponded to 
the patient's  HLA haplotype as determined by lymphocyte typing (14):  A-2, w-31, 
Bw-21, w-35, and Cw-4. In addition, isoenzyme markers for five traits  (glyoxalase I, 
phosphoglucornutase-1, phosphoglucomutase-3, esterase D, and glutamate-oxaloace- 
tate transaminase)  revealed no discrepancy between the phenotypes of the three DX 
melanoma cell lines. 
Typing  of  DX-1,  DX-2,  and  DX-3  Cells for  HLA-DR  and  Other Cell Surface 
Antigens.  Table  I  summarizes  the  results  of serological  tests  using  a  battery  of 
conventional  and  monoclonal  reagents  identifying differentiation  antigens  on  the 
surface of melanoma cells (8,  15-17).  Expression of HLA-DR determinants showed 
the  most  striking  difference. DX-1  and  DX-3  express  HLA-DR  products,  whereas 
DX-2 does not. The lack of detectable HLA-DR determinants on the DX-2 line was 
confirmed by absorption analysis  (Fig.  2)  and by radioimmunoprecipitation experi- 1768  MELANOMA  HETEROGENEITY AND SURFACE ANTIGEN EXPRESSION 
FIG.  1 C.  Photomicrograph  of cell line DX-3 (×220). See text for description. 
ments  (see  below).  Less marked, but  characteristic  differences were detected  in  the 
expression of a  number of other cell surface antigens (Table I). 
Glycoprotein  Profiles  of  DX  Melanoma  Lines  Detected  by  Cell  Surface  Labeling 
Procedures.  Melanomas express a  characteristic  pattern  of cell surface glycoproteins 
that can be detected by surface radiolabeling procedures (12).  All melanoma cell lines 
have  two  major  groups  of glycoproteins  with  molecular  weights  of  ~90,000  and 
120,000.  These glycoproteins are so highly sialylated that  they cannot be labeled by 
galactose-oxidase-[3H]borohydride without prior neuraminidase treatment; this prop- 
erty is a peculiarity of melanoma cells which distinguishes them from other cell types. 
Application of this approach to DX melanoma has demonstrated  differences in  the 
surface characteristic of the three DX cell lines (Fig. 3).  DX-2 and DX-3 have rather 
similar profiles of cell surface glycoproteins in the high molecular weight region, with 
the  components  of 90,000  and  120,000  mol  wt  being  particularly  prominent.  As 
expected,  these components were not  labeled  by galactose-oxidase-[3H]borohydride 
without prior neuraminidase treatment.  DX-2 had an additional prominent compo- 
nent  of 60,000  mol wt which was only weakly labeled in  DX-3.  DX-3 differed from 
DX-2 in having two major glycoproteins in the low molecular weight region of 32,000 ALBINO  ET  AL.  1769 
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FIo.  2.  HLA-DR  phenotype of DX-1,  DX-2, and  DX-3  melanoma cell lines as determined by 
absorption  analysis.  A,  rabbit  anti-HLA-DR  serum;  B,  human-anti-HLA-DR  serum;  C,  mouse 
monoclonal anti-HLA-DR serum. Typing sera (see Table I)  diluted according to end point were 
absorbed with equal volumes of the indicted cell types, Residual reactivity of recovered serum was 
tested on SK-MEL-93 (an HLA-DR-expresslng melanoma cell line). DX-1, DX-3, and SK-MEL-28 
absorbed HLA-DR reactivity. DX-2 and SK-MEL-28 Clone A (a non-HLA-DR-expressing cloned 
variant) did not absorb HLA-DR reactivity. ©, DX-2; O, DX-1; V, DX-3; ~7, SK-MEL-28; R, SK- 
MEL-28 Clone A; I-'1, unabsorbed serum. 
and  27,000.  Using specific antisera,  these components were shown  to be HLA-DR 
subunits, thus confirming the serological data presented above. DX-1 monolayer cells 
demonstrated unusual surface-labeling characteristics in comparison with DX-1 sus- 
pension cells, DX-2, and DX-3 cells. Using the neuraminidase-galactose-oxidase-[3H] 
borohydride procedure, only one major glycoprotein of 90,000 mol wt was labeled in 
DX-1  monolayer cells;  treatment  with  galactose-oxidase-[3H]borohydride without 
neuraminidase  did  not  label  any  specific components.  The  DX-1  monolayer cells 1770  MELANOMA HETEROGENEITY AND SURFACE ANTIGEN  EXPRESSION 
TABLE  I 
Serological Typing for Cell Surface Antigens Expressed by Three Melanoma Cell Lines Derived  from 
Patient DX 
Antigen 
system de- 
tected 
Source of antibody*  Reference or description 
Cell lines 
DX- 1  DX-2  DX-3 
Serum titers ×  10 -3 
HLA-DR  Rabbit antiserum  18  64  0  256 
HLA-DR  Human serum  Transfused individual  50  0  300 
HLA-DR  Mouse monoclonal  18, 19  50  0  500 
HLA-A, B, C  Mouse monoclonal  20  320  1,200  320 
Mel- 1  Human serum  8  3  3  0.4 
O~4 (gp 150)  Mouse monoclonal  15  i ,000  4,000  1,000 
MI7 (gp95)  Mouse monoclonal  15  50  3,000  250 
05  Mouse monoclonal  15  1,500  1,500  625 
R24  Mouse monoclonal  15  3  100  3 
Rs  Mouse monoclonal  15  1,000  3,000  3,000 
D14  Mouse monoclonal  Mouse immunized with  50  500  25 
E20  Mouse monoclonal  DX-2 melanoma cell line  256  1,000  1,000 
A27 
Al2s 
A12a 
Mouse monoclonal  Mouse immunized with SK-  8  12  12 
Mouse monoclonal  MEL-19 melanoma celt line  1  25  50 
Mouse monoclonal  8  200  12 
Llo~  Mouse monoclonal  Mouse immunized with SK-  50  800  50 
MEL-33 melanoma cell line 
MCTazs  Mouse monoclonal  Mouse immunized with cul-  5,000  10,000  50 
tured human cutaneous mel- 
anocytes 
* Mouse monoclonal reagents:  sera or ascites fluid ofnu/nu mice. 
labeled very poorly with periodate-[3H]borohydride,  also in contrast  to DX-I  suspen- 
sion cells, DX-2, and DX-3 cells. Since periodate, in the concentration used, selectively 
oxidizes sialic acid,  the latter  results  would  suggest  that  the surface  glycoproteins of 
DX- 1 monolayer cells have very few sialic acid residues. On the other hand, hydrolysis 
with  neuraminidase  clearly removes sialic acid  to expose  galactose  residues  that  are 
subsequently  labeled  with  [ZH]borohydride.  A  possible  explanation  is  that  DX-1 
monolayer cells have substituted  sialic acid residues that are not oxidized by periodate 
but can be hydrolyzed by neuraminidase.  This possibility needs further investigation, 
but  whatever  the  explanation,  the  results  demonstrate  that  DX-I  monolayer  cells 
have surface characteristics  quite different  from those of DX-1  suspension  cells. 
Autologous  Typing with Sera from Patient DX 
DmECT  SEROLOGICAL  TESTS.  Sera  from  patient  DX  were  tested  for  antibody 
reacting with surface antigens of autologous DX-1, DX-2, and DX-3 cells. Autologous 
reactions were seen with DX-2 target cells, but  not with DX-1  or DX-3 cells, or with 
DX  fibroblasts.  Fig. 4  shows the reactions  of DX  serum  obtained  in  September  1978 ALBINO  ET  AL.  1771 
Fic.  3.  Fluorograms of SDS-PAGE  of DX  melanoma  cell  lines  labeled  by  treatment  with  1, 
neuraminidase-galactose-oxidase-[SH]borohydride, 2, galactose oxidase-[SH]borohydride, and 3, per- 
iodate-[SH]borohydride.  Molecular weight  standards:  myosin,  200,000;  ,8-galactosidase,  120,000; 
phosphorylase, 98,000;  bovine serum albumin, 68,000;  ovalbumin, 43,000;  concanavalin A, 28,000. 
NS, nonspecific component labeled by [SH]borohydride alone. Arrows indicate HLA-DR subunits. 
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FIG. 4.  Reactivity of DX  serum  for  autologous  DX-2  melanoma cells  as determined by three 
serological assays. O, PA; V, IA; (3, anti-yG. 
with DX-2 cells as determined in three serological test systems. Antibody was detected 
in PA and anti-TG  , but not in IA. Ion-exchange chromatography of DX sera showed 
that all reactivity for DX-2 cells resided in the IgG fraction. As PA gave highest titers 
with DX sera, all further analysis was done with this assay. 
TIME-CouRsE OF DX AUTOLOGOUS REACTIVITY.  Fig. 5 shows the PA reactivity of 
a  sequential  series of specimens of DX sera for DX-2 melanoma cells.  No reactions 
were  seen  with  the  initial  serum  specimens.  Antibody  was  first  detected  in  sera 
obtained in September 1978  and peak levels were found in January  1979.  Reactivity 
then began to fall, and for the past  17 mo no autologous reactivity has been detected. 
Vaccination  with  allogeneic or autologous melanoma cells  (see above)  appeared  to 
have no influence on antibody levels. 
ABSORPTION ANALYSIS OF DX SERA; DEFINITION  OF DX ANTIGEN. The reactivity of 
DX  sera  (obtained  September  1978)  for  DX-2  cells  was  analyzed  by  qualitative 
absorption  tests.  Fig.  6  illustrates  an  absorption  test  and  Table II summarizes  the 
results of the analysis. Only DX-2 cells absorbed autologous reactivity completely. In 
some tests, DX-1 and DX-3 cells gave a pattern of partial absorption, suggesting that 
the  cells express the  same antigenic  determinants  detected  by DX serum  on  DX-2 1772  MELANOMA  HETEROGENEITY  AND SURFACE ANTIGEN EXPRESSION 
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FIc. 5.  Reactivity of sequential serum specimens from patient  DX for DX-2 melanoma cells. 
Serological assay: PA. Titer refers to serum dilution showing 50% positive target cells. Arrows 
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FIG. 6.  Qualitative absorption analysis of the PA reactivity of DX serum for DX-2 melanoma 
cells. DX reactivity was completely absorbed by DX-2 melanoma cells grown in FBS or in normal 
human serum. DX-I, DX-3, SK-MEL-13, SK-MEL-28, DX normal skin fibroblasts and DX EBV- 
transformed B cells did not absorb DX reactivity. O, DX-2 (FCS);  O, DX-2 (HS); V, DX-I; ~7, DX- 
3; II, DX normal skin fibroblasts; f-I, DX EBV-transformed B cells; A, SK-MEL-13; A, SK-MEL- 
28; ~, unabsorbed serum. 
cells,  but  at  a  quantitatively lower  level.  To  investigate  this  possibility,  double 
absorptions of DX  sera  were  carried  out.  Fig.  7  shows  that  two  successive serum 
absorptions with DX-1 or DX-3 removed reactivity for DX-2 cells; double absorptions 
with eight allogeneic melanoma cell lines did not reduce DX reactivity. 
As shown  in Table II, no cell  type other  than  DX-1,  DX-2,  or  DX-3  absorbed 
autologous reactivity. These tests included 45 cell lines of allogeneic melanoma, and 
a wide range of cell types other than melanoma. Absorption with DX autologous skin 
fibroblasts and Epstein-Barr virus (EBV)-transformed B cells did not remove autolo- 
gous reactivity. To exclude the participation of antigens related to FBS in the observed 
reactions,  DX-2  melanoma cells were  grown  for  at  least  four passages  in  medium 
supplemented with  normal human serum  (HS)  only. As seen  in Fig.  6,  these cells 
absorbed autologous reactivity as efficiently as cells grown in FBS. The results indicate 
the detection of a class 1 melanoma antigen, which we have designated DX, restricted 
to autologous DX melanoma cells. 
ALLOOENEIC TYPINC WITH DX  SERA.  DX  sera  reacted  in direct  tests  with  9-10 ALBINO  ET  AL. 
TABLE  II 
Summary of Results of Absorption Analysis of the PA Reactivity of DX Serum  for A utologous 
Melanoma Cells 
1773 
Positive ab~rption  Negative  absorption 
Autologous  cuhure~ mel- 
anoma cells: 
DX-2 (FBS) 
DX-2 (Human serum) 
Partial Absorption 
DX- 1 
DX-3 
Autologous  cultured cells: 
Skin fibroblasts 
EBV-transformed  B cells 
Allogeneic  cultured  melanoma 
SK-MEL- 13  SK-MEL-72 
SK-MEI¢ 18  SK-MEL-73 
SK-MEL-19  SK-MEL-75 
SK-ME1,-20  SK-MEL-78 
SK-MEI~23  SK-MEL-79 
SK-MEL-27  SK-MEL-80 
SK-MEL-28  SK-MEL-94 
SK-MEL-29  SK-MEI~95 
SK-MEL-30  SK-MEL-100 
SK-MEI.-31  SK-MEL- 101 
SK-MEI~33  SK-MEL-110 
SK-MEI~37  SK-MEL-118 
SK-MEL-40  SK-MEL-119 
SK-MEL-42  SK-MEI,- 122 
SK-MEL-56  SK-MEI~I23 
SK-MEL-57  SK-MEL-125 
SK-MEL-60  SK-MEI~I27 
SK-MEL-61  SK-MEL- 129 
SK-MEL-63  SK-MEL- 130 
SK:MEL-64  SK-ME1,-131 
cells: 
SK-MEI:I32 
SK-MEL-133 
SK-MEL-140 
SK-ME1,- 147 
MeWo 
Allogeneic cultured  nonmeianoma  cells: 
Astroeytoma:  U-373, U-138, AN, AS 
Breast Cancer: MCF-7, BT-20, AIAb 
Renal  Cancer:  SK-RC-I, SK-RC-2,  SK-RC-6, 
SK-RC-8,  SK-RC-9,  SK-RC-10,  Caki-I 
Other cancers: HT-29 (colon), ME-180 (cervix), 
SK-GR-I (testicular),  SK LE-I,L (lung), 5627 
(bladder), MOLT-4 (leukemia) 
EBV-transformed  B cells: BF, CS, BD, AV, DS, 
AE 
Skin tlbroblasts:  AS, BE, EM, ER, FB 
Fetal cells: skin, choroid, brain, liver, Flow 4000, 
Flow 5000 
AIIogeneic noncuhured  cells: 
A, B, O erythrocytes, adult brain 
Xenogeneie  cells and serum: 
VERO  (monkey  kidney  cell  line),  BHK/21 
(hamster kidney cell llne), BALB/3T3 (mouse 
cell line), sheep  erythrocytes,  fetal bovine  se- 
runl 
allogeneic melanoma cell  lines. It seemed most likely that  these allogeneic reactions 
were due to antibodies to HLA-related antigens in DX sera (DX is the mother of four 
children). If this were the case, EBV-transformed B cells from dorrors of the allogeneic 
melanomas should remove all  reactivity  from DX sera for the allogeneic  melanoma 
cells. In four such pairs of allogeneic B cells and melanoma cells, B cells absorbed all 
allogeneic DX reactivity, but did not alter autologous reactivity of DX sera for DX- 
2 cells. 
CHARACTERISTICS OF  THE  DX  ANTIGEN. Absorption  tests  indicate  that  the  DX 
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Fxo.  7.  Effect of double absorptions of DX serum with DX-1, DX-2, or DX-3 melanoma cell lines. 
Aliquots of 1:20 diluted  DX sera were absorbed with equal  volumes of the indicated  cell types for 
30  min  at  20°C,  then  for  30 min  at  0°C.  After  removal  of absorbing  cells by centrifugation,  the 
recovered DX sera were similarly absorbed a second time with equal volumes of the same cell type. 
The doubly  absorbed  DX  sera were then  tested  for  residual  reactivity  for  DX-2  melanoma  cells. 
O, DX-2; O, DX-I; V, DX-3;  ~7, SK-MEL-28;  I,  SK-MEL-29;  I--I, unabsorbed serum. 1774  MELANOMA HETEROGENEITY  AND  SURFACE ANTIGEN EXPRESSION 
determinant is heat  labile (100°C  for 5  min)  and trypsin sensitive.  Efforts to immu- 
noprecipitate the antigen from radiolabeled DX-2 cell extracts have been unsuccessful 
(see Discussion). 
SEROLOGICAL COMPARISON OF TWO  CLASS  1 ANTIGENS: AU  AND  DX.  AU  is  the 
prototype  class  1  melanoma  antigen  (1).  To  determine  the  possible  serological 
relatedness of DX  and  AU  antigens,  reciprocal absorption  tests with  DX  and  AU 
typing sera were carried out  (Fig. 8).  DX-2  melanoma removed DX  reactivity, but 
not AU reactivity. AU melanoma (SK-MEL-28) absorbed AU reactivity, but not DX 
reactivity. Both AU and DX-2 melanoma cells absorbed reactivity from a  typing sera 
detecting  the  Mel-1  antigen,  an  antigen  related  to  melanocyte  differentiation  (8). 
Another melanoma line (SK-MEL-19) did not absorb DX, AU, or Mel-1  reactivity. 
Characteristics of Three Additional Cell Lines from Patient DX. Three additional cell lines 
have been established from separate metastases removed from patient DX in August 
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Fio.  8.  Serological typing for DX, AU, and Mel-1 antigens. Qualitative absorption  was carried 
out with end point-diluted typing serum absorbed with equal volumes of the indicated cell types. 
Serological assay: PA. Typing systems: A, DX:DX serum reacted with DX-2 melanoma  line; B, 
AU: AU serum reacted with AU melanoma line (SK-MEL-28); and C, Mel-l: human serum NS 
124  reacted  with  SK-MEL-28  melanoma  line. O,  DX-2;  O,  SK-MEL-28;  V,  SK-MEL-29;  V, 
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1980  (DX-4) and December 1980  (DX-5, DX-6). Table III summarizes the features 
of these new cell lines in relation to the DX-1, DX-2, and DX-3 cell lines. 
Discussion 
As a  consequence of our interest in the humoral immune response of patients to 
autologous melanoma cells, we have established melanoma cell lines from over 150 
individuals.  Virtually  all  the  lines  were  derived  from  metastatic  disease,  and  the 
success rate for establishing melanoma cell lines over the past 6 yr has ranged from 
15-40%.  (Our experience with primary melanoma has been more limited, primarily 
because the specimen is usually required in its entirety for microstaging.) A comparison 
of established melanoma cell lines from different individuals shows striking variation 
in  morphology,  growth  rate,  pigmentation,  and  pattern  of surface  antigens  and 
glycoproteins. This  phenotypic heterogeneity of cultured  melanoma  may reflect a 
corresponding  diversity  in  the  phenotype  of normal  cells  undergoing  melanocyte 
differentiation, with malignant transformation fixing a cell within a particular stage 
in  the  melanoblast  ~  melanocyte  lineage.  Additional  factors,  either  genetic  or 
epigenetic, must  also be involved in the generation of this diversity, because clones 
derived from the same melanoma cell line show stable phenotypic differences (21; A. 
Albino,  unpublished  observations).  This could  mean  that  melanomas  are  initially 
derived from more than one clone of transformed cells, or that the disease is in fact 
initiated  by  a  single  transformed  clone  with  stable  variants  of the  clone  being 
generated throughout the course of the disease. Either explanation could account for 
the phenotypic diversity of cell lines derived from the different metastatic deposits of 
melanomas removed from patient DX over the course of 2 yr. Although some degree 
of variation can be expected to result from prolonged in vitro passage, it appears most 
likely that the differences that distinguish these three lines represent characteristics of 
major or minor cell populations present in vivo that have emerged as the predominant 
phenotype  in  vitro.  For  instance,  DX-2  and  DX-3  cell  lines,  derived  from  two 
independent metastatic lesions located some  10 cm apart and removed at  the same 
time, differed morphologically and in the quantitative expression of HLA-DR antigens 
when  tested  20  d  after explantation.  Similarly,  three  new  cell  lines  derived  from 
metastatic  lesions of this  patient  (DX-4,  DX-5,  and  DX-6),  tested  within  2  d  of 
TABLE  III 
Characteristics of Six Established Melanoma Cell Lines Derived  from Separate Metastases of Patient DX 
Autologous  typing  for DX  antigen 
Cell  Morphology  Pigmen-  HLA-DR*  Mel-l*  Direct  test  Single  Double 
line  tation  absorp-  absorp- 
(titer)  tion~-  tion:~ 
DX-1  Spindle  (monolayer)  +  +  +  -  (<1:10)  -  or -¢-  + 
plus suspension 
DX-2  Spindle  +  -  +  +  (1:80-1:320)  +  + 
DX-3  Epithelioid  -  +  +  -  (<1:10)  -  or +  + 
DX-4  Epithelioid  +  -  -  -  (<1 : 10)  -  - 
DX-5  Cuboidal  -  +  +  -  (< 1 : 10)  -  ± 
DX-6  Spindle/epithelioid  +  +  +  -  (< 1:10)  -  ± 
* As determined  in direct  serological  tests  and  by absorption  analysis. 
See Figs. 6  and  7. +,  complete  absorption;  ±,  partial  absorption;  -,  no absorption. 1776  MELANOMA  HETEROGENEITY  AND  SURFACE  ANTIGEN  EXPRESSION 
explantation, also showed stable phenotypic differences in the expression of HLA-DR 
antigens. 
Analysis of these melanoma cell lines derived from patient DX also clearly illustrates 
the  importance of phenotypic  variation  in studies  of tumor immunity.  If DX-I  or 
DX-3, or the more recently derived DX-4, DX-5, or DX-6 cell lines had been the only 
targets  available  to  study  the  autologous  reactions  of sera  from  patient  DX,  the 
presence of antibody defining a  class  1 melanoma antigen  would  have been missed, 
since  only  DX-2  expressed  this  antigen  in  sufficient  quantity  to  be  detected  by 
sensitive serological assays. In our past studies of humoral immunity to melanoma, we 
have generally depended on a single target cell line to test the reactivity of autologous 
sera.  Antibodies  to  class  1  antigens  have  been  found  only  rarely--in  4  patients, 
including patient DX, out of a  total of 75 patients studied  (10).  This low frequency 
of class  1  reactivity  may  have  several  explanations,  ranging  from  lack  of class  1 
antigens  on  the  majority  of melanomas,  to  lack  of antibody  to  melanoma  class  1 
antigens in the majority of melanoma patients. It is also possible that the serological 
assays used are of insufficient sensitivity to detect antibodies of low titer, low avidity, 
or of an  unusual  subclass, or that  cells expressing class  1 antigens  have a  selective 
disadvantage in tissue culture.  Experience with the six melanoma lines derived from 
patient  DX emphasizes the  critical  nature  of the  target  cell  in  identifying  class  1 
antigens and suggests that class  1 reactivity may in  fact be more common than our 
past studies with only a single cell line from each melanoma patient would indicate. 
We are investigating this possibility by establishing several cell lines from each new 
melanoma patient, either from individual  metastases, as in the case of DX, or from 
different clones isolated directly from the same melanoma specimen. 
With  the serological identification  of four melanoma antigens of the class  1 type, 
certain  similarities  have  become  evident.  By  definition,  each  shows  an  absolute 
restriction to autologous melanoma cells, not being found on autologous normal cells 
or  any  normal  or  malignant  cell  of  allogeneic  or  xenogeneic  origin.  Antibodies 
detecting three class  1 antigens  (AU, BI, and DX)  belong to the IgG class, whereas 
antibody  to  the  BD  antigen  is  IgM.  AU,  the  prototype class  1 antigen,  has  been 
characterized as a glycoprotein, as indicated by its affinity for Lens culinaris lectin (7). 
It is solubilized by papain, and molecular sizing of the solubilized AU antigen shows 
it to have a molecular weight in the range of 25,000-40,000.  From the studies done to 
date, DX and BI antigens also have characteristics of glycoproteins. Despite relatively 
high  titers  of sera detecting  AU,  BI, and  DX antigens,  it  has not  been  possible to 
immunoprecipitate radiolabeled cell extracts with these human antibodies as a  way 
to characterize class 1 antigens further. For this reason, much effort is now going into 
preparing mouse or human monoclonal antibody to these antigens. The key question 
is whether class 1 antigens are closely related products coded for by the same locus or 
structurally unrelated products coded for by distinct loci. Purification and biochemical 
characterization of a  series of class  1 antigens and mapping of their coding genes by 
somatic cell genetics and gene cloning should provide ways to address this question. 
Summary 
Three established lines of melanoma cells were derived from anatomically distinct 
metastases occurring  in  a  single  patient  (DX).  The lines,  DX-1,  DX-2,  and  DX-3, 
showed  marked  phenotypic  diversity,  as  indicated  by  characteristic  differences  in ALBINO Err  AL.  1777 
growth rate,  morphology, pigmentation,  and  the expression  of surface antigens  and 
glycoproteins.  DX-1  and  DX-3 expressed  HLA-DR  products,  whereas  DX-2 lacked 
HLA-DR expression. DX-1, DX-2~ and DX-3 could also be distinguished on the basis 
of the profile of radiolabeled  glycoproteins. Additional quantitative differences in the 
surface antigenic  phenotype of the three  cell  lines were revealed by serological tests 
with a battery of monoclonal and conventional antibodies defining melanoma differ- 
entiation antigens. In tests for autologous humoral immunity to melanoma cells, sera 
from patient DX were found to have IgG antibody that reacted with surface antigens 
of DX-2 cells;  no autologous reactivity was seen  with  DX-1  or DX-3 target  cells or 
with three more recently established melanoma cell lines from patient DX. Absorption 
analysis  indicated  that  the  antigen  detected  by DX sera on  DX-2  cells  is  a  class  1 
melanoma antigen, having been detected only on DX-2 cells and in much lower but 
demonstrable  amounts  on DX-1  and  DX-3 cells.  No other cell  type,  including  DX 
normal  fibroblasts,  DX  B  cells,  or 45  allogeneic  melanoma  cell  lines  expressed  the 
class  1 antigen of DX melanoma.  The fact that only one of the melanoma cell  lines 
derived from patient  DX was a  suitable target for the detection of autologous class  1 
reactivity has implications  for the study of human tumor antigens and may explain 
why antibody  to class  1 antigens  has been  found so  infrequently  in  past  studies  of 
melanoma patients. 
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